Drugs / VX-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06770933 | Feb 2025 → Mar 2027 expected | diabetic retinopathy | Vantage Biosciences Ltd | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06770933 ↗ |